The NHS in England has approved a new daily pill, linzagolix, for the treatment of endometriosis, which affects approximately 1.5 million women in the UK. Symptoms include chronic pain, heavy periods, and fatigue. Linzagolix joins relugolix combination therapy as the second take-at-home pill for endometriosis treatment. Unlike relugolix, linzagolix requires additional 'add back' hormone therapy to manage hormone suppression effects. The approval reflects advancements in care options, potentially reducing the need for painful hospital treatments and enhancing quality of life for women suffering from this condition.
The new pill, linzagolix, provides a promising new option for over 1,000 women in the UK to better manage endometriosis symptoms.
Although there is no cure for endometriosis, linzagolix represents a significant step in treatment flexibility, offering patients an alternative to hospital visits.
Collection
[
|
...
]